We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+29.22%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$514M
AUM Growth
+$32.4M
Cap. Flow
-$86.5M
Cap. Flow %
-16.83%
Top 10 Hldgs %
73.17%
Holding
39
New
7
Increased
8
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$21.7M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$9.08M
3
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$7.08M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.05M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$6.73M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$71.2M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$13M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$10.9M
4
PRQR icon
ProQR Therapeutics
PRQR
+$9.44M
5
ARRY
Array Biopharma Inc
ARRY
+$8.32M

Sector Composition

Rank Sector Weight
1 Healthcare 70.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
26
DELISTED
Aptose Biosciences, Inc.
APTO
$986K 0.19%
+370
New +$1.11M
VXRT
27
DELISTED
Vaxart
VXRT
$976K 0.19%
39,627
– –
ANTH
28
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$884K 0.17%
69,953
– –
SPHS
29
DELISTED
Sophiris Bio, Inc.
SPHS
$573K 0.11%
1,060,283
+460,283
+77% +$1.07M
ARDX icon
30
Ardelyx
ARDX
$1.25B
– –
-453,541
Closed -$6.45M
PRQR icon
31
ProQR Therapeutics
PRQR
$251M
– –
-549,000
Closed -$9.44M
PTN
32
Palatin Technologies
PTN
$13.9M
– –
-601
Closed -$698K
QURE icon
33
uniQure
QURE
$2.93B
– –
-106,500
Closed -$981K
RGLS
34
DELISTED
Regulus Therapeutics
RGLS
– –
-1,542
Closed -$1.26M
TRVN
35
DELISTED
Trevena, Inc.
TRVN
– –
-1,790
Closed -$7.18M
PRTK
36
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-12,500
Closed -$304K
RCPT
37
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-1,146,300
Closed -$71.2M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2014 Portfolio in Review

As of Q4 2014, BVF Inc held 39 positions worth $514M, up 6.7% from $482M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BVF Inc withdrew a net $86.5M in Q4 2014, closing 8 positions and reducing 6 holdings. Its most notable exit was RECEPTOS INC COM STK (DE), an estimated $71.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 65% a quarter earlier.

Against the trend, BVF Inc opened a new position in Forward Pharma A/S American Depositary Shares worth $21.9M.

  • BVF Inc's largest Q4 2014 buy was Forward Pharma A/S American Depositary Shares: 150,340 shares worth $21.9M.
  • BVF Inc added most to Cascadian Therapeutics, Inc. in Q4 2014, an estimated $7.05M increase.
  • BVF Inc's biggest Q4 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $13M.
  • BVF Inc fully exited RECEPTOS INC COM STK (DE) in Q4 2014, selling an estimated $71.2M.
  • BVF Inc's ten largest holdings make up 73% of its $514M portfolio in Q4 2014.
  • BVF Inc opened 7 new positions and closed 8 in Q4 2014.
  • BVF Inc's portfolio value rose 6.7% quarter-over-quarter to $514M.

Based on BVF Inc's 13F filing for Q4 2014, filed 17 Feb 2015.